HIM
AMRX icon

Hillsdale Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Hillsdale Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.24M Buy
743,679
+29,150
+4% +$391K 0.25% 68
2025
Q4 		$9M Sell
714,529
-1,500
-0.2% -$17.2K 0.25% 70
2025
Q3 		$7.17M Buy
716,029
+715,229
+89,404% +$6.42M 0.22% 117
2025
Q2 		$6.47K Buy
800
+50
+7% +$377 ﹤0.01% 570
2025
Q1 		$6.29K Buy
+750
New +$6.26K ﹤0.01% 540
2024
Q2 		– Sell
-699,719
Closed -$4.24M – 580
2024
Q1 		$4.24M Buy
699,719
+115,100
+20% +$649K 0.34% 108
2023
Q4 		$3.55M Buy
584,619
+541,000
+1,240% +$2.41M 0.29% 135
2023
Q3 		$184K Buy
+43,619
New +$163K 0.02% 352
2022
Q4 		– Sell
-861,716
Closed -$1.74M – 550
2022
Q3 		$1.74M Hold
861,716
– – 0.16% 155
2022
Q2 		$2.74M Hold
861,716
– – 0.22% 147
2022
Q1 		$3.59M Sell
861,716
-8,200
-0.9% -$36.3K 0.23% 148
2021
Q4 		$4.17M Sell
869,916
-2,600
-0.3% -$13K 0.28% 125
2021
Q3 		$4.66M Buy
872,516
+85,700
+11% +$431K 0.36% 87
2021
Q2 		$4.03M Buy
786,816
+175,616
+29% +$998K 0.32% 110
2021
Q1 		$4.11M Buy
+611,200
New +$3.39M 0.34% 97

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Hillsdale Investment Management's AMRX Position: Q1 2026 in Review

Hillsdale Investment Management increased its Amneal Pharmaceuticals (AMRX) stake by 4.1% in Q1 2026, buying an estimated $391K and bringing the position to 743,679 shares worth $9.24M. The position accounts for 0.25% of the portfolio, ranked #68.

Hillsdale Investment Management first reported a position in AMRX in Q1 2021 and has held it in 15 quarters since. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Hillsdale Investment Management held 743,679 shares of Amneal Pharmaceuticals worth $9.24M as of Q1 2026.
  • Hillsdale Investment Management bought 29,150 Amneal Pharmaceuticals shares in Q1 2026, an estimated $391K.
  • Amneal Pharmaceuticals made up 0.25% of Hillsdale Investment Management's portfolio in Q1 2026, its #68 holding.
  • Hillsdale Investment Management first reported a position in Amneal Pharmaceuticals in Q1 2021 and has held it in 15 quarters since.
  • 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.